Articles, guides, and regulatory updates from our community.
A 2026 study found BPC-157 and hybrid analogs may inhibit acetylcholinesterase, a key enzyme in Alzheimer's disease. Learn what the research means.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's development barriers, formulation challenges, and why human clinical data remains critically limited.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's biopharmaceutical challenges, pharmacokinetic gaps, and the barriers standing between preclinical promise and human trials.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines why BPC-157 lacks approved formulations, validated dosing, and completed Phase II trials despite 30+ years of preclinical data.
By Peptide Association Research Team
A 2026 review in JBJS Reviews examines the evidence, safety, and antidoping implications of injectable peptides used in sports medicine and orthopaedics.
By Peptide Association Research Team
A 2026 structured review examines injectable peptides for musculoskeletal recovery. Learn what the evidence, safety data, and antidoping rules mean for athletes.
By Peptide Association Research Team
How peptides like BPC-157, larazotide, and KPV are being studied for gastrointestinal conditions — from inflammatory bowel disease to intestinal barrier repair.
By Peptide Association Editorial Team
An honest assessment of BPC-157 research — separating the extensive animal data from the limited human evidence, and what providers should tell patients asking about this popular peptide.
By Peptide Association Editorial Team